Blueprint for EECA countries, first edition
Première Conférence ministérielle mondiale de l’OMS
Mettre fin à la tuberculose à l’ère du développement durable : une réponse multisectorielle
Moscou, Fédération de Russie, 16-17 novembre 2017
Scientific advice
Prevention and control of communicable diseases in prison settings.
World's largest Science, Technology & Medicine Open Access book publisher
Chapter 7 from the book People's Movements in the 21st Century - Risks, Challenges and Benefits
The modules (1-12) are based on materials originally developed by FIND, KNCV and Cepheid, and are in PowerPoint format for country customization. Depending on the audience, modules may be selected and adapted according to need (e.g. basic users, supervisors, clinicians). Topics covered include: Over...view of TB and diagnostics, biosafety, specimen collection, procurement, installation, Xpert MTB/RIF technology, results interpretation, reporting, troubleshooting, maintenance, a clinical guide, and quality assurance.
Please download each manual directliy from the website
more
Key Populations Brief
Accessed November 2017
Rapport sur les populations clès
Accessed November 2017
L’OMS a ciblé 17 maladies comme des Maladies Tropicales Négligées. Ces maladies sont très différentes les unes des autres, mais elles ont comme point commun de toucher principalement les populations les plus pauvres. Elles maintiennent dans la pauvreté les populations ayant initialement un n...iveau de développement faible. Ces maladies coexistent au sein des mêmes populations, augmentant de ce fait leur vulnérabilité.
more
Suggested language and usage for tuberculosis communications
First edition
Accessed November 2017
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis.
Accessed in November 2017.
3rd Edition – July 2017
www.msfaccess.org
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
National Tuberculosis and Leprosy Conrol Programme